Major bleeding risk assessment in atrial fibrillation patients taking vitamin K antagonists

Detalhes bibliográficos
Autor(a) principal: Pivatto Júnior, Fernando
Data de Publicação: 2015
Outros Autores: da Silva, André Luís Ferreira, Bezerra, Indira Valente, Pires, Leonardo Martins, Amon, Luís Carlos, Blaya, Marina Bergamini, Scheffel, Rafael Selbach
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Clinical and Biomedical Research
Texto Completo: https://seer.ufrgs.br/index.php/hcpa/article/view/54273
Resumo: Background. The use of risk scores for the assessment of major bleeding and stroke in patients with atrial fibrillation (AF) helps evaluate the risks and benefits of oral anticoagulation therapy. The aim of this study was to describe the percentage of  patients receiving anticoagulants for non-valvular AF with a high risk of major bleeding based on the HAS-BLED score, as well as identify potential modifiable risk factors of bleeding and compare the risk of major bleeding with the risk of stroke.Methods. Retrospective cohort study involving patients of the anticoagulation outpatient clinic of the Division of Internal Medicine at Hospital de Clínicas de Porto Alegre. Major bleeding risk was estimated based on the HAS-BLED score and stroke risk was determined using the CHADS2 and CHA2DS2-VASc scores.Results. Sixty-three patients were investigated (mean age 74.3±10.9 years). The median HAS-BLED score was 2 points, 19 (30.2%) patients had a score ≥ 3 (high risk). The most prevalent modifiable risk factors were labile TP/INR (36.5%) and concomitant use of drugs (30.2%). The absolute risk of major bleeding based on the HAS-BLED score was higher than the risk of stroke in three (4.8%) and four (6.3%) patients in comparison with the CHADS2 and CHA2DS2-VASc score, respectively.Conclusions. We concluded that the percentage of patients with high risk of major bleeding is similar to the rate found in the national literature (30.2%). In addition, the most prevalent modifiable risk factors in our cohort were labile TP/INR and concomitant drug use.  
id UFRGS-20_73bbf06136e8ada037552f8caf5a3310
oai_identifier_str oai:seer.ufrgs.br:article/54273
network_acronym_str UFRGS-20
network_name_str Clinical and Biomedical Research
repository_id_str
spelling Major bleeding risk assessment in atrial fibrillation patients taking vitamin K antagonistshemorrhagestrokeatrial fibrillationwarfarinphenprocoumonBackground. The use of risk scores for the assessment of major bleeding and stroke in patients with atrial fibrillation (AF) helps evaluate the risks and benefits of oral anticoagulation therapy. The aim of this study was to describe the percentage of  patients receiving anticoagulants for non-valvular AF with a high risk of major bleeding based on the HAS-BLED score, as well as identify potential modifiable risk factors of bleeding and compare the risk of major bleeding with the risk of stroke.Methods. Retrospective cohort study involving patients of the anticoagulation outpatient clinic of the Division of Internal Medicine at Hospital de Clínicas de Porto Alegre. Major bleeding risk was estimated based on the HAS-BLED score and stroke risk was determined using the CHADS2 and CHA2DS2-VASc scores.Results. Sixty-three patients were investigated (mean age 74.3±10.9 years). The median HAS-BLED score was 2 points, 19 (30.2%) patients had a score ≥ 3 (high risk). The most prevalent modifiable risk factors were labile TP/INR (36.5%) and concomitant use of drugs (30.2%). The absolute risk of major bleeding based on the HAS-BLED score was higher than the risk of stroke in three (4.8%) and four (6.3%) patients in comparison with the CHADS2 and CHA2DS2-VASc score, respectively.Conclusions. We concluded that the percentage of patients with high risk of major bleeding is similar to the rate found in the national literature (30.2%). In addition, the most prevalent modifiable risk factors in our cohort were labile TP/INR and concomitant drug use.  HCPA/FAMED/UFRGS2015-07-03info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionPeer-reviewed ArticleAvaliado por Paresapplication/pdfhttps://seer.ufrgs.br/index.php/hcpa/article/view/54273Clinical & Biomedical Research; Vol. 35 No. 2 (2015): Clinical and Biomedical ResearchClinical and Biomedical Research; v. 35 n. 2 (2015): Clinical and Biomedical Research2357-9730reponame:Clinical and Biomedical Researchinstname:Universidade Federal do Rio Grande do Sul (UFRGS)instacron:UFRGSenghttps://seer.ufrgs.br/index.php/hcpa/article/view/54273/pdf_7Pivatto Júnior, Fernandoda Silva, André Luís FerreiraBezerra, Indira ValentePires, Leonardo MartinsAmon, Luís CarlosBlaya, Marina BergaminiScheffel, Rafael Selbachinfo:eu-repo/semantics/openAccess2024-01-19T14:26:26Zoai:seer.ufrgs.br:article/54273Revistahttps://www.seer.ufrgs.br/index.php/hcpaPUBhttps://seer.ufrgs.br/index.php/hcpa/oai||cbr@hcpa.edu.br2357-97302357-9730opendoar:2024-01-19T14:26:26Clinical and Biomedical Research - Universidade Federal do Rio Grande do Sul (UFRGS)false
dc.title.none.fl_str_mv Major bleeding risk assessment in atrial fibrillation patients taking vitamin K antagonists
title Major bleeding risk assessment in atrial fibrillation patients taking vitamin K antagonists
spellingShingle Major bleeding risk assessment in atrial fibrillation patients taking vitamin K antagonists
Pivatto Júnior, Fernando
hemorrhage
stroke
atrial fibrillation
warfarin
phenprocoumon
title_short Major bleeding risk assessment in atrial fibrillation patients taking vitamin K antagonists
title_full Major bleeding risk assessment in atrial fibrillation patients taking vitamin K antagonists
title_fullStr Major bleeding risk assessment in atrial fibrillation patients taking vitamin K antagonists
title_full_unstemmed Major bleeding risk assessment in atrial fibrillation patients taking vitamin K antagonists
title_sort Major bleeding risk assessment in atrial fibrillation patients taking vitamin K antagonists
author Pivatto Júnior, Fernando
author_facet Pivatto Júnior, Fernando
da Silva, André Luís Ferreira
Bezerra, Indira Valente
Pires, Leonardo Martins
Amon, Luís Carlos
Blaya, Marina Bergamini
Scheffel, Rafael Selbach
author_role author
author2 da Silva, André Luís Ferreira
Bezerra, Indira Valente
Pires, Leonardo Martins
Amon, Luís Carlos
Blaya, Marina Bergamini
Scheffel, Rafael Selbach
author2_role author
author
author
author
author
author
dc.contributor.author.fl_str_mv Pivatto Júnior, Fernando
da Silva, André Luís Ferreira
Bezerra, Indira Valente
Pires, Leonardo Martins
Amon, Luís Carlos
Blaya, Marina Bergamini
Scheffel, Rafael Selbach
dc.subject.por.fl_str_mv hemorrhage
stroke
atrial fibrillation
warfarin
phenprocoumon
topic hemorrhage
stroke
atrial fibrillation
warfarin
phenprocoumon
description Background. The use of risk scores for the assessment of major bleeding and stroke in patients with atrial fibrillation (AF) helps evaluate the risks and benefits of oral anticoagulation therapy. The aim of this study was to describe the percentage of  patients receiving anticoagulants for non-valvular AF with a high risk of major bleeding based on the HAS-BLED score, as well as identify potential modifiable risk factors of bleeding and compare the risk of major bleeding with the risk of stroke.Methods. Retrospective cohort study involving patients of the anticoagulation outpatient clinic of the Division of Internal Medicine at Hospital de Clínicas de Porto Alegre. Major bleeding risk was estimated based on the HAS-BLED score and stroke risk was determined using the CHADS2 and CHA2DS2-VASc scores.Results. Sixty-three patients were investigated (mean age 74.3±10.9 years). The median HAS-BLED score was 2 points, 19 (30.2%) patients had a score ≥ 3 (high risk). The most prevalent modifiable risk factors were labile TP/INR (36.5%) and concomitant use of drugs (30.2%). The absolute risk of major bleeding based on the HAS-BLED score was higher than the risk of stroke in three (4.8%) and four (6.3%) patients in comparison with the CHADS2 and CHA2DS2-VASc score, respectively.Conclusions. We concluded that the percentage of patients with high risk of major bleeding is similar to the rate found in the national literature (30.2%). In addition, the most prevalent modifiable risk factors in our cohort were labile TP/INR and concomitant drug use.  
publishDate 2015
dc.date.none.fl_str_mv 2015-07-03
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
Peer-reviewed Article
Avaliado por Pares
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://seer.ufrgs.br/index.php/hcpa/article/view/54273
url https://seer.ufrgs.br/index.php/hcpa/article/view/54273
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv https://seer.ufrgs.br/index.php/hcpa/article/view/54273/pdf_7
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv HCPA/FAMED/UFRGS
publisher.none.fl_str_mv HCPA/FAMED/UFRGS
dc.source.none.fl_str_mv Clinical & Biomedical Research; Vol. 35 No. 2 (2015): Clinical and Biomedical Research
Clinical and Biomedical Research; v. 35 n. 2 (2015): Clinical and Biomedical Research
2357-9730
reponame:Clinical and Biomedical Research
instname:Universidade Federal do Rio Grande do Sul (UFRGS)
instacron:UFRGS
instname_str Universidade Federal do Rio Grande do Sul (UFRGS)
instacron_str UFRGS
institution UFRGS
reponame_str Clinical and Biomedical Research
collection Clinical and Biomedical Research
repository.name.fl_str_mv Clinical and Biomedical Research - Universidade Federal do Rio Grande do Sul (UFRGS)
repository.mail.fl_str_mv ||cbr@hcpa.edu.br
_version_ 1799767053724286976